QPT Share Price

Open 0.11 Change Price %
High 0.11 1 Day 0.00 0.00
Low 0.10 1 Week -0.02 -15.38
Close 0.11 1 Month 0.03 37.50
Volume 168500 1 Year 0.05 83.33
52 Week High 0.19
52 Week Low 0.04
QPT Important Levels
Resistance 2 0.12
Resistance 1 0.12
Pivot 0.11
Support 1 0.10
Support 2 0.10
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
MVN 0.10 42.86%
MVN 0.10 42.86%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
CUI 0.02 100.00%
CUI 0.02 100.00%
GRI 0.02 100.00%
GRI 0.02 100.00%
GTC 0.02 100.00%
GTC 0.02 100.00%
BVQ 0.02 100.00%
CZH 0.02 100.00%
CZH 0.02 100.00%
CZH 0.02 100.00%
More..
CVE Canada Top Losers Stocks
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
SB 0.03 -40.00%
SB 0.03 -40.00%
More..

Quest PharmaTech Inc (CVE: QPT)

QPT Technical Analysis 3
As on 7th Dec 2016 QPT Share Price closed @ 0.11 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.06 & Buy for SHORT-TERM with Stoploss of 0.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
QPT Target for December
1st Target up-side 0.22
2nd Target up-side 0.26
3rd Target up-side 0.3
1st Target down-side 0.1
2nd Target down-side 0.06
3rd Target down-side 0.02
QPT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.questpharmatech.com
QPT Address
QPT
8123 Roper Road NW
Edmonton, AB T6E 6S4
Canada
Phone: 780-448-1400
Fax: 780-416-0324
Interactive Technical Analysis Chart Quest PharmaTech Inc ( QPT CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Quest PharmaTech Inc
QPT Business Profile
Quest PharmaTech Inc., a clinical stage biotechnology company, engages in the development and commercialization of oncology products. It develops a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, immune-adjuvants, and photodynamic therapy. The company's lead product candidate, Oregovomab, an immunotherapeutic product for the treatment of ovarian cancer and is under a multi-center Phase IIb clinical trials in Italy and the United States. The company also develops MUC1 program that has completed phase I clinical trials for the treatment of cancer tumors; and SL052, a photosensitizer product, which is under phase I clinical trials and is intended for the treatment of prostate cancer. Quest PharmaTech Inc. has a strategic relationship with with AD Biotech Co., Ltd. The company is headquartered in Edmonton, Canada.